Industry Briefs: January 28, 2013
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AAIPharma has expanded its laboratory service offerings, capabilities, and instrumentation at its laboratory technology center in Wilmington, North Carolina. Read More
Baxter International has agreed to acquire the investigational hemophilia compound OBI-1 from Inspiration BioPharmaceuticals, as well as other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction is subject to bankruptcy court and regulatory approvals. Read More
Idenix Pharmaceuticals, a biopharmaceutical company engaged in the discovery and development of drugs for treating human viral diseases, has formed a nonexclusive collaboration with Johnson & Johnson subsidiary Janssen Pharmaceuticals for the clinical development of all-oral, direct-acting, antiviral Hepatitis C combination therapies. The collaboration will evaluate combinations including IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor, simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen and Medivir AB, and TMC647055, a once-daily non-nucleoside polymerase inhibitor, boosted with low-dose ritonavir, being developed by Janssen. Read More
Medicago, a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and virus-like particles, has formed a collaboration agreement with Mitsubishi Chemical Holdings Corporation (MCHC) to develop technology for plant production. The objectives of the collaboration are to evaluate MCHC’s plant factory system, a closed-cultivation system, to produce nicotiana benthamiana plants for protein production using Medicago’s technologies. Read More
Sanofi’s Auvi-Q (epinephrine injection, USP) is now available in US retail pharmacies with a prescription from a healthcare provider. Auvi-Q is an epinephrine autoinjector with audio and visual cues for the emergency treatment of allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q features a design that guides patients and caregivers, step-by-step, through the injection process. Read More
Xceleron, a bioanalytical-service provider, has formed a partnership with the China-based solid-state research CRO Crystal Pharmatech that is designed to provide drug developers early bioavailability data and optimized solid-state forms and formulations. Read More
People News
AAIPharma has appointed James Fife as senior director of parenteral operations for its manufacturing facility in Charleston, South Carolina. Read More
Bayer announced that Jörg Reinhardt, chairman of the board of management of Bayer HealthCare and a member of the Bayer executive council, will not renew his contract when it expires in summer 2013. Read More
Cytovance Biologics named Maria Lopez vice-president of quality. Read More
GlaxoSmithKline has appointed Hans Wijers to its board as a nonexecutive director. Read More
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
